Last $1.00 USD
Change Today 0.00 / 0.00%
Volume 85.8K
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

stellar biotechnologies inc (SBOTF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - $2.36
52 Week Low
07/21/14 - $0.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stellar biotechnologies inc (SBOTF) Related Businessweek News

No Related Businessweek News Found

stellar biotechnologies inc (SBOTF) Details

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

stellar biotechnologies inc (SBOTF) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

stellar biotechnologies inc (SBOTF) Key Developments

Stellar Biotechnologies, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:30 PM

Stellar Biotechnologies, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Stellar Biotechnologies, Inc. Announces Consolidated Earnings Results for the Year Ended August 31, 2014

Stellar Biotechnologies, Inc. announced consolidated earnings results for the year ended August 31, 2014. For the year, the company reported total revenues of $372,132 compared to $545,469 for the same period a year ago. Net loss was $8,439,523 against $14,495,779 a year ago. The lower loss in the current year was primarily affected by noncash changes in fair value of warrant liability. Basic and diluted loss per common share was $0.11 against $0.28 a year ago. Net cash used in operating activities was $4,266,707 against $2,795,823 a year ago.

Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies

Stellar Biotechnologies, Inc. and Araclon Biotech SL announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease. The purpose of the agreement is to ensure a stable supply to Araclon of Stellar KLH(TM) for the ongoing clinical development of Araclon's Alzheimer's drugs, including the development of manufacturing processes, production capacity and regulatory support. Under the agreement, Araclon will manage and fund all product development and regulatory submissions for its products. Stellar will supply GMP-grade Stellar KLH(TM) protein and will provide technical and regulatory support to Araclon. The agreement requires Stellar to deliver the first batch of Stellar KLH(TM) to Araclon by December 31, 2014. Araclon and Stellar have entered into a mutually exclusive contract for the supply of KLH for Araclon's beta amyloid peptide in the Alzheimer's space throughout the term of the agreement for use in Araclon's upcoming clinical trials with an active immunotherapy against Alzheimer's disease at agreed prices. Stellar and Araclon have agreed upon first negotiation rights for the exclusive supply of Stellar KLH(TM) in connection with the potential future commercialization by Araclon of its beta amyloid-targeting immunotherapy products. The agreement has an initial five-year term, which may be renewed by Araclon, if necessary, for additional one-year periods.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBOTF:US $1.00 USD 0.00

SBOTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBOTF.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBOTF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 209.7x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 176.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STELLAR BIOTECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at